Congratulations to @SMitragotri for receiving the Founder’s Award from the Controlled Release Society, recognizing outstanding contributions to the field as well as exemplary leadership and impact on the scientific community.
@wyssinstitute@CRS
As the @CRSScience annual meeting starts in Philadelphia. I am checking the annual Proceedings and CD-ROM programs in my office. Impressive that CRS has done so much for the field in the last 52 years. Cc: @MariaJVicent1@JustinHanesPhD@SMitragotri
During the next session at #CancerEngineeringSummit, experts shared solutions to hard problems.
Samir Mitragotri, PhD (@SMitragotri) discussed advancing cytotoxic T cell therapies.
David Odde, PhD (@davidodde) shared insights on glioblastoma and the mechanics of T cell migration in cancer progression.
Karen Lu, MD (@karenluMD) highlighted the power of multidisciplinary teamwork, sharing a real-world example of bridging basic science and clinical trials in ovarian cancer.
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases.
I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known.
People can contact me directly at my first name (as written in my profile) at https://t.co/ubo0zQRMn0.